Q-VANT Biosciences

Join the conversation on Veterinary vaccines adjuvants! ?? SPI Pharma is hosting an insightful webinar on March 13th to explore advancements in veterinary vaccine adjuvants and how they enhance immune responses in animal health. At Q-VANT Biosciences, we support sustainable, high-performance adjuvants that drive One Health—recognizing the deep connection between animal, human, and environmental health. #AnimalHealth #VaccineAdjuvants #OneHealth

Following Vishnu's recent visit to South Korea, through our partnership with SPI Pharma, we reaffirm our support in vaccine development from the adjuvant perspective in ensuring global access to scalable adjuvants that enhance vaccine efficacy and long-term protection. #VaccineDevelopment #Adjuvants #QS21 #GlobalHealth

?? Advancing Equine Health with Saponin Adjuvants This?#WorldHorseDay, we’re proud to highlight the critical role of saponin adjuvants in enhancing equine immunization. This not only protects horses but also supports the One Health approach, which safeguards animal, human, and environmental health through stronger disease prevention. Saponins enhance the immune response by stimulating antibody production and cell-mediated immunity, ensuring better protection against diseases such as African Horse Sickness, Anthrax, Herpes, Influenza, Streptococcus, Tetanus, and the West Nile virus. Two studies demonstrated that an equine influenza vaccine formulated with tetanus toxoid induces long-term protection—lasting at least 15 and 18 months. At?Q-VANT Biosciences, we’re committed to pioneering sustainable adjuvant technologies that support the health of animals and humans alike. https://lnkd.in/e6hf4X4C #EquineHealth #VaccineScience #SaponinAdjuvants #WorldHorseDay?

?? Q-SAP technology enables the secured saponin supply for vaccines. Saponin adjuvants are sourced, extracted and purified from Quillaja saponaria tree, an endemic species of Chile. The Bark of quillaja, which represents 1 to 6% of the biomass, is a vital protection for the tree survival and grows too slowly to support the vaccine industry (25 years before harvest). For this reason, saponin adjuvants for new vaccine developments shall be sourced from renewable biomass obtained from plantations. After 8 years of development, Q-SAP by?Q-VANT Biosciences, plus access to Quillaja plantations, makes using fast-growing and renewable biomass for QS-21 and other saponin adjuvants possible. This increases the yield by more than 1000 times and significantly reduces the cost per dose compared to other alternatives. #VaccineDevelopment #Adjuvant #SecureSupply #Quillaja #QS21

?? On this World Cancer Day, we highlight the promising potential of Quillaja saponins in cancer treatment, supported by the latest research. HPV tumors: A vaccine formulation incorporating QS-21 and CpG achieved sustained complete regression in over 70% of oral and 80% of vaginal HPV tumors. This response correlated with robust total and HPV-antigen-specific CD8+ T cell activation, as well as natural killer dendritic cell induction [1]. Saponin + CpG in Cryoablation: Peritumoral vaccination following cryoablation generated a strong in situ immune response, leading to high tumor rejection rates. This approach involves cryoablation of the tumor, followed by peritumoral administration of a CpG + Quillaja saponin adjuvant 30 minutes later. Remarkably, this strategy resulted in a 90% survival rate [2]. Saponin-Induced T Cell Responses: Saponins promoted a high frequency of E7-specific CD8+ T cells and polyfunctional cytokine-secreting lytic T cells, demonstrating significant therapeutic efficacy against well-established C3.43 tumors [3]. These findings underscore the potential of Quillaja saponins as a potent immunotherapeutic tool in cancer treatment. To date, 57 clinical trials have been conducted exploring saponin-based cancer therapies. Q-VANT Biosciences is committed to advancing this field through R&D collaborations to develop novel cancer treatments. https://lnkd.in/drnuZeE #WorldCancerDay?#CancerResearch #OpenAccess References: 1.????O’Hara, M. P., Yanamandra, A. V. & Sastry, K. J., 2024. Immunity from NK Cell Subsets Is Important for Vaccine-Mediated Protection in HPV+ Cancers. Vaccines, 12(2), p. 206. 2.????Raaijmakers, T. K. et al., 2020. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes. Journal for ImmunoTherapy of Cancer, 8(1). 3.????Da Silva, D. M. et al., 2019. Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. Vaccine, 37(22), pp. 2915-2924.

?? Today, on the World Day of Neglected Tropical Diseases (NTDs), we join the global effort to raise awareness about these devastating illnesses, the suffering they cause, and the urgent need for action to eradicate, control, and eliminate them. At Q-VANT Biosciences, we’re honoured to highlight how saponin adjuvants provide innovative solutions for vaccines targeting neglected tropical diseases. Their potential has been demonstrated in several studies, including: ·????????Dengue: Clements et al., 2010 ·????????Chikungunya: Halleng?rd et al., 2014; VLP vaccine by Metz et al., 2013 ·????????Leishmaniasis: Lage et al., 2020 ·????????Rabies: Wang et al., 2024 ·????????Schistosomiasis: Zhang et al., 2018; You et al., 2015, 2018 ·????????Trypanosomiasis: Autheman et al., 2021; Caeiro et al., 2020; Bontempi et al., 2015, 2017; Scott et al., 1985 Q-VANT Biosciences is actively seeking R&D collaborations to advance the development of saponin-adjuvanted vaccines for NTDs. By providing open-access, sustainable adjuvants, we aim to foster a more accessible and equitable approach to immunization against these diseases. #NTD #Immunization #GlobalHealth #SustainableAdjuvant

??Quillaja saponin adjuvants are currently incorporated in the two approved malaria vaccines [1,2] and many prototypes are in development [3-5]. Indeed, a recent publication from Mehrizi’s working group showed the vaccine efficacy of a prototype that uses cell transversal protein (PfCelTOS) as an antigen and QS-21 as a key adjuvant [6]. QS-21 significantly improves the protection and immune response against Malaria in vaccinated animals when combined with other adjuvants such as Poly I:C. This improvement is most likely due to the resulting high levels of Malaria-specific antibodies and robust T cellular responses.?The results showed that the dual adjuvant mixture of Poly I:C and QS-21 (PQ) induce protection, through an immune mechanism comparable to those achieved with more complex triple adjuvant mixtures (MPL/Poly I:C/QS-21), but with fewer adjuvants required, suggesting cost-effectiveness and improved safety profiles. References: 1.??????WHO, 2021. WHO recommends groundbreaking malaria vaccine for children at risk. 2.??????WHO, 2023. WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization. 3.??????Pourhashem, Z. et al., 2024. Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants. PlosOne, 19(7). 4.??????Reinke, S. et al., 2023. Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms. Cell Report medicine, Volume 4. 5.??????Yu, X. et al., 2024. Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine. International Immunopharmacology, Volume 131. 6.??????Pirahmadi, S. et al., 2025. Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum. Biochemical and Biophysical Research Communications, Volume 748.

According to the WHO, 60% of emerging infectious diseases that are reported globally come from animals, and 75% of new human pathogens detected in the last 3 decades have been originated in animals. As we navigate the dynamic landscape of veterinary disease, it's crucial to spotlight the pivotal role of saponin adjuvants in enhancing vaccine efficacy, demonstrating compatibility and versatility across a spectrum of diseases. From viral (FMD, Influenza), bacterial (Manheimia, Bacillus, Mycoplasma) and parasitic (Equinococosis, Haemonchus) infections among many others, saponin adjuvants have been recognized for their immunostimulatory prowess. Sole saponins or in combination with aluminium, oil emulsion, present a unique ability to stimulate robust immune responses, amplifying the effectiveness of vaccines. With the second generation of saponin adjuvants, Q-VANT Biosciences continues to develop the full potential of these adjuvants, propelling us closer to safer, more effective, and more sustainable health for both humans and animals. https://lnkd.in/eAxxdZuG #VaccineInnovation #Adjuvants #Immunotherapy #MedicalAdvancements

?? Wishing you a Happy End of the Year from Q-VANT Biosciences! As we step into 2025, we are filled with gratitude for the partnerships, developments, and progress we shared with you in the past year in advancing vaccine adjuvant technology and supply security. This year, our team has worked to contribute to the global effort in developing and scaling up the processes to create and deliver safer, effective and more sustainable saponin adjuvants and therapies: ·????????In collaboration with Tulane University, financed by NIH, we started to develop an Oral adjuvant platform https://lnkd.in/gtD6y6Vz ·????????The construction finished for our state-of-the-art Quillaja-based adjuvant factory. ·????????Our team grew. ·????????Supporting SPI Pharma at The World Vaccine Congress, CBIOPC, CPHI. ·????????We received interest from 31 vaccine developers and manufacturers in our saponin adjuvants. Wishing our colleagues and partners a healthy and impactful year ahead. More breakthroughs will be coming next year from Q-VANT Biosciences, through collaboration, and generating positive impact in the field of infectious diseases and therapy. Cheers to a Happy New Year! ?? #VaccineAdjuvant #NewYear2025

Embracing the spirit of Christmas Spirit at Q-VANT! ?? The Q-VANT Biosciences team wishes all patients suffering from a disease and their families the very best in this festive season. We hope you have a healthy, loving, and memorable Christmas! In the spirit of giving, we're grateful for the opportunity to contribute to the well-being of patients worldwide through enabling sustainable, and open-access vaccine adjuvants. I'm wishing everyone a happy, healthy, and hopeful Christmas! #Patients #Christmas #OpenAccessToHealth